Ramdev Konijeti, MD
Urology · la Jolla, CANPI 1578708715
Payments from drug & device makers
Across 163 payments — averaging $125.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Urogen Pharma, Inc.$2K
- Boston Scientific$2K
- Intuitive Surgical$2K
- EDAP Technomed Inc$379
- Johnson & Johnson$325
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$13,47566%
- Grants$1211%
- Travel & lodging$7424%
- Food & beverage$6,12030%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $10,273 |
| Urogen Pharma, Inc. | 5 | $2,492 |
| Boston Scientific | 10 | $2,428 |
| Intuitive Surgical | 17 | $2,273 |
| EDAP Technomed Inc | 4 | $379 |
| Johnson & Johnson | 13 | $325 |
| AbbVie(2 entities) | 13 | $294 |
| Astellas Pharma US Inc | 11 | $198 |
| Merck | 8 | $183 |
| Progenics Pharmaceuticals, Inc. | 3 | $174 |
| AstraZeneca | 6 | $131 |
| E.r. Squibb & Sons, L.L.C. | 7 | $127 |
| Medtronic | 1 | $121 |
| Bayer | 6 | $114 |
| Ferring Pharmaceuticals Inc. | 5 | $100 |
| Neotract Inc. | 4 | $87 |
| Myriad Genetic Laboratories, Inc. | 4 | $76 |
| Novartis | 3 | $73 |
| Blue Earth Diagnostics | 3 | $72 |
| Amgen | 3 | $72 |
| Teleflex LLC | 3 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Seagen Inc. | 3 | $61 |
| Eisai Inc. | 3 | $51 |
| Dendreon Pharmaceuticals LLC | 2 | $41 |
| Histosonics, Inc. | 1 | $37 |
| EMD Serono, Inc. | 2 | $37 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Immunitybio, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| 180 Medical, Inc. | 1 | $20 |
| Richard Wolf Medical Instruments Corp. | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$10,161
- ZUSDURI$2,399
- SpaceOAR VUE System - 10mL$2,137
- Da Vinci Surgical System$1,451
- PYLARIFY$125
- REZUM$118
- rezum Generator$109
How this compares
$20,536 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 51 | $59,882 |
| Tamsulosin Hcl | 238 | $5,075 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 231 | $4,804 |
| Dutasteride | 52 | $3,782 |
| Testosterone | 40 | $3,234 |
| Methenamine Hippurate | 20 | $2,930 |
| Finasteride | 138 | $2,066 |
| Estradiol | 22 | $1,401 |
| Oxybutynin Chloride | 45 | $541 |
| CefuroximeCefuroxime Axetil | 38 | $532 |
| Doxazosin Mesylate | 14 | $341 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $191 |
| Sildenafil Citrate | 23 | $139 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $107 |
| Ondansetron OdtOndansetron | 21 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $198 | $59,88251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.
Other urology in la Jolla
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.